Among a growing cluster of Pittsburgh biotechs, you'll find BlueSphere Bio, an early-stage company discovering T cell receptors to leverage against tumor-specific antigens in individual cancer patients. Its leader, CEO Keir Loiacono, Esq., works with a sense of urgency inspired by his own cancer journey. The Business of Biotech toured BlueSphere's state-of-the-art facility and sat down with Loiacono to discuss the company's vision for the future of personalized, adoptive cell therapy. Listen now!
In this article, we discuss CDMO assessment and show how to construct an agreement between partners that favors fluid communication and alignment of business objectives — crucial for a fruitful sponsor-CDMO relationship to diminish overall risk for both.
ISR explains how LSL’s CDMO Leadership Awards and the corresponding market research data can be used by biopharma companies to make more informed CDMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.
Frequently, during the CMC development period, novel compositions, processes, and conditions may be discovered that may be used to strategically extend the product's life cycle.
Decentralized clinical trials (DCTs) offer clear benefits to patients and the overall success of the trial, but it can be difficult to know how to address this challenge. This three-stage framework approach will enable you to assess your organization’s current clinical trial innovation maturity and build a plan from there.
This webinar reviews the impact of regulatory changes related to elemental impurities testing, guidance on the best routes to compliance, and an overview of the elemental impurities risk assessment process.
Explore ongoing work to harness different types of HDR templates in order to build cutting-edge systems with the potential to enable point-of-care cell and gene therapy manufacture.
Explore four key interconnected variables exerting pressure on therapeutics developers to improve their processes earlier in the product’s development.
It is possible to develop key performance indicators (KPIs) for your medical affairs team through building a framework for understanding success that embraces both quantitative and qualitative metrics.
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
Connect With Life Science Leader:
This website uses cookies to ensure you get the best experience on our website. Learn more
